Single-Cell Transcriptomics Reveals That Metabolites Produced by Paenibacillus bovis sp. nov. BD3526 Ameliorate Type 2 Diabetes in GK Rats by Downregulating the Inflammatory Response

Zhenyi Qiao,Xiaohua Wang,Huanchang Zhang,Jin Han,Huafeng Feng,Zhengjun Wu
DOI: https://doi.org/10.3389/fmicb.2020.568805
IF: 5.2
2020-12-22
Frontiers in Microbiology
Abstract:Chronic low-grade inflammation is widely involved in the development and progression of metabolic syndrome, which can lead to type 2 diabetes mellitus (T2DM). Dysregulation of proinflammatory and anti-inflammatory cytokines not only impairs insulin secretion by pancreatic β-cells but also results in systemic complications in late diabetes. In our previous work, metabolites produced by Paenibacillus bovis sp. nov. BD3526, which were isolated from Tibetan yak milk, demonstrated antidiabetic effects in Goto–Kakizaki (GK) rats. In this work, we used single-cell RNA sequencing (scRNA-seq) to further explore the impact of BD3526 metabolites on the intestinal cell composition of GK rats. Oral administration of the metabolites significantly reduced the number of adipocytes in the colon tissue of GK rats. In addition, cluster analysis of immune cells confirmed that the metabolites reduced the expression of interleukin (IL)-1β in macrophages in the colon and increased the numbers of dendritic cells (DCs) and regulatory T (T reg ) cells. Further mechanistic studies of DCs confirmed that activation of the WNT/β-catenin pathway in DCs promoted the expression of IL-10 and transforming growth factor (TGF)-β, thereby increasing the number of T reg cells.
microbiology
What problem does this paper attempt to address?
The paper aims to explore the therapeutic effects and mechanisms of metabolites from a bacterium named *Paenibacillus bovis* sp. nov. BD3526 on type 2 diabetes (T2DM). Specifically, the researchers used single-cell transcriptome sequencing technology (scRNA-seq) to investigate the impact of BD3526 metabolites on the gut cell composition of Goto-Kakizaki (GK) rats and found that these metabolites can improve the symptoms of type 2 diabetes by downregulating inflammatory responses. ### Main Issues: 1. **The relationship between chronic low-grade inflammation and type 2 diabetes**: Chronic low-grade inflammation plays a key role in the development of type 2 diabetes, particularly by affecting insulin secretion and systemic complications. 2. **Mechanism of action of BD3526 metabolites**: The researchers aim to understand how BD3526 metabolites improve the symptoms of type 2 diabetes by regulating gut immune cells. ### Specific Research Content: - **Experimental Design**: By orally administering BD3526 metabolites to GK rats, the researchers observed their impact on gut cell composition. - **Results Analysis**: Using single-cell RNA sequencing technology, it was found that BD3526 metabolites significantly reduced the number of adipocytes in the colon tissue of GK rats and decreased the expression of interleukin-1β (IL-1β) in macrophages, while increasing the number of dendritic cells (DCs) and regulatory T cells (Treg cells). - **Mechanism Study**: Further research indicated that activating the Wnt/β-catenin pathway in DCs can promote the expression of interleukin-10 (IL-10) and transforming growth factor-β (TGF-β), thereby increasing the number of Treg cells and reducing inflammatory responses. ### Summary: The main purpose of this paper is to reveal the impact of BD3526 metabolites on the gut cell composition of type 2 diabetes GK rats through single-cell transcriptome sequencing technology and to explore the specific mechanisms by which these metabolites improve diabetes symptoms by regulating immune cells.